Search This Blog

Friday, November 8, 2024

Humacyte FDA review of acellular tissue engineered vessel BLA for Vascular Trauma ongoing

 Results from the V007 Phase 3 clinical trial of the ATEV in arteriovenous (AV) access for hemodialysis patients presented at American Society of Nephrology’s Kidney Week 2024 -

Long-term results from the humanitarian program where the ATEV was used to treat vascular injuries suffered during the Ukraine conflict were presented at the U.S. Department of Defense’s foremost scientific meeting -

- Conference call and live webcast at 8:30 a.m. ET today -

Conference Call and Webcast Details

Title:Humacyte Third Quarter 2024 Financial Results and Corporate Update
Date:Friday, November 8, 2024
Time:8:30 a.m. ET
Conference Call Details:Toll-Free: 1-877-704-4453
International: 1-201-389-0920
Conference ID #: 13749485
Call meTM Feature (avoid waiting for operator):Click Here
Webcast:Webcast Link - Click Here
  

A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company’s website for at least 30 days.

https://www.globenewswire.com/news-release/2024/11/08/2977606/0/en/Humacyte-Third-Quarter-2024-Financial-Results-and-Business-Update.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.